Tuesday Jul 22
Endocyte, Inc. Announces Second Quarter 2014 Earnings Conference Call
Endocyte, Inc., announced today that the company will host a conference call on Tuesday, July 29, at 4:30 p.m. EDT to discuss its second quarter 2014 financial results and provide an operational update.
Endocyte Hits New 12-Month Low at $6.01
Shares of Endocyte reached a new 52-week low during trading on Monday , StockRatingsNetwork.com reports.
Endocyte Receives Average Rating of "Buy" from Brokerages
Endocyte has received an average recommendation of "Buy" from the eleven ratings firms that are covering the company, AnalystRatingsNetwork.com reports .
Press release distribution, EDGAR filing, XBRL, regulatory filings
This report upd... )--Wuaki.tv, the on-demand streaming service, has added hundreds of new British movie titles to the company's extensive on-demand catalogue for rental and purchase.
Zacks Upgrades Endocyte to Outperform
The firm currently has a $7.90 price objective on the stock. Zacks 's price target indicates a potential upside of 17.91% from the stock's previous close.
Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in...
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Endocyte, Inc. of the August 25, 2014 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against Endocyte and the Company's President and Chief Executive Officer.
Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been...
Gainey McKenna & Egleston announces that a class action lawsuit has been filed in the United States District Court for the Southern District of Indiana on behalf of all persons who purchased or otherwise acquired the securities of Endocyte, Inc. during the period between March 21, 2014 and May 2, 2014 .
Endocyte Spiked Sharply On Rumored Resumption Of Cancer Drug Trial
Endocyte rose sharply in early afternoon trading Monday from near a 52-week low on rumors the company may resume a trial of its cancer drug candidate, vintafolide.